Forbion’s Post

At Artax Biopharma, we are developing first-in-class Nck modulators to treat T cell mediated autoimmune disease such as #psoriasis, #atopicdermatitis, and more. We're excited by the progress we've been making in the development of our first novel mechanism, AX-158, as we rapidly approach phase 2 trials for psoriasis treatment with first results expected in Q4 2024. We are simultaneously developing additional Nck modulator candidates for #autoimmunediseases with AX-194 undergoing preclinical testing to enter Phase 1 trials. Learn more about our candidate pipeline on our recently updated website here: https://lnkd.in/eqq3eSTK #clinincaltrials #immunology

Our portfolio company Insilico Medicine announced that following the Orphan Drug Designation (ODD) granted in June 2024, its potential best-in-class TEAD inhibitor, ISM6331, received IND approval from the US FDA in July 2024 for the treatment of mesothelioma. This marks Insilico Medicine's ninth innovative molecule to receive clinical trial approval. Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, said, "Approximately 10% of cancer patients have abnormalities in the Hippo signaling pathway. ISM6331, which targets the TEAD family, offers a new therapeutic strategy with broad potential applications, including enhancing chemotherapy efficacy, boosting tumor immunotherapy, optimizing small molecule targeting, and overcoming resistance. We are committed to leveraging AI to advance medicine and bring new hope and potential therapies to patients with rare and challenging diseases." #Biotech #Pharmaceuticals #CancerResearch #DrugDiscovery #AIDD #OrphanDrugs #QimingPortfolio #QimingHealthcare

At Artax Biopharma, we are developing first-in-class Nck modulators to treat T cell mediated autoimmune disease such as #psoriasis, #atopicdermatitis, and more. We're excited by the progress we've been making in the development of our first novel mechanism, AX-158, as we rapidly approach results from our phase 2 trials for psoriasis treatment with first results expected in December 2024. We are simultaneously developing additional Nck modulator candidates for #autoimmunediseases with AX-194 undergoing preclinical testing to enter Phase 1 trials. Learn more about our candidate pipeline here: https://lnkd.in/eqq3eSTK #clinincaltrials #immunology

Breakthrough at ARVO 2024 Calm Water Therapeutics (CWT) unveiled exciting results from their second clinical trial at the ARVO 2024 conference, demonstrating the clear efficacy of their proprietary polymer formulation in treating the signs and symptoms of dry eye disease. Conducted in partnership with Ora, the CWT-002 trial evaluated multiple dry eye signs and symptoms over a 30-day period, directly comparing CWT's innovative formulation to the current market leader. CWT's treatment exhibited clear superiority, validating the potential of their cutting-edge technology. CWT is advancing our polymer technology to address not only dry eye disease but also Antibody Drug Conjugate keratopathy, a growing problem that currently lacks an effective solution. This breakthrough could bring much-needed relief to those from these debilitating eye conditions. https://lnkd.in/edz67hah #dryeyedisease #occupationalhealth #oncology

🗞 IN THE NEWS: In a clinical trial at NIH’s National Cancer Institute (NCI), researchers tested the combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (called ViPOR) in 50 patients with DLBCL, the most common type of lymphoma. The treatment shrank tumors substantially in 26 of 48 (54%) evaluable patients, with 18 (38%) of those patients’ tumors disappearing entirely, known as a complete response. At two years, 36% of all patients were alive and 34% were free of disease. These benefits were seen mainly in people with two specific subtypes of DLBCL. ➡ Read more in this piece by MedPage Today: https://lnkd.in/eK75QQyd Additional outlets that have covered ViPOR include Healio, European Pharmaceutical Review, HealthDay News, Clinical Trials Arena, etc. #CancerResearch #Lymphoma #ClinicalTrial #Health #Medicine

#Congratulations 🎊 to #BIAMember Accession Therapeutics Limited who have filed an application for a first-in-human trial of TROCEPT-01 ➡️ https://ow.ly/eF6L50TmbVk TROCEPT-01 is a leading #Anticancer #immunotherapy, designed to showcase the program in solid tumours and provide clinical validation of the #TROCEPT platform 👏 Their team focused on getting TROCEPT-01, encoding a clinically validated immune #checkpoint ✅ inhibitor (ICI) transgene and with the potential to expand the success of ICIs through high tumour-localised production, to the clinic as efficiently as possible 🚀

1. PharmAust has rebranded as Neurizon Therapeutics, seeing a share price increase of approximately 90% year-to-date. 2. The company is advancing its lead drug, monepantel, now called NUZ-001, targeting neurodegenerative diseases, starting with ALS. 3. A Phase 2/3 clinical trial for NUZ-001 is set to begin in Q1 2025 as part of the HEALEY ALS Platform Trial. 4. NUZ-001 has received orphan drug designation from the FDA, providing benefits such as tax credits and market exclusivity. 5. The drug inhibits the mTOR pathway to help clear misfolded proteins in ALS, potentially slowing disease progression. 6. Early results from trials show NUZ-001 may reduce ALS symptom decline by 39% and improve patient survival rates significantly. 7. The market for ALS therapies exceeds $2 billion annually, with a high demand for effective treatments due to the lack of current cures. 8. Neurizon's strategy focuses on improving patient access, partnering with neurologists, and exploring the drug's potential for other neurodegenerative diseases.

Immix Biopharma and its subsidiary Nexcella have advanced their CAR-T therapy, NXC-201, for relapsed/refractory AL amyloidosis to an expansion cohort in the U.S. trial NEXICART-2. After successfully dosing patients in the initial cohort, the new cohort will explore higher doses of the therapy, aiming to expand enrollment. Previous trials showed promising results, with high overall response rates in patients. This marks a key milestone for CAR-T in treating AL amyloidosis, which currently lacks FDA-approved treatments https://lnkd.in/eRyghAtA

𝗧𝗵𝗲 𝗣𝗵𝗮𝗿𝗺𝗮 𝗡𝗲𝘄𝘀 𝟮𝟬𝟮𝟰 Decoding the News: Key Insights from the News Article ⬇ Below are the links to the respective news articles: 1. Coherus BioSciences sells its last biosimilar Udenyca to Intas Pharmaceuticals for up to $558M as the company homes in on novel cancer meds https://lnkd.in/ghWx3RSF  2. Reckitt shells out $200M to expand its Mucinex production site in North Carolina https://lnkd.in/gjUjmbi3 3. Are You Using Next-Gen Sequencing to inform AAV product and process quality? Here are 4 reasons you should https://lnkd.in/gUp4WrSk 4. Biopharma Takes on Deadly Brain Cancer After Decades of Failure https://lnkd.in/eGUyTy6s 5. Digital Twins Could Augment Clinical Research, Help Ease Data Disparities https://lnkd.in/e2kzD3v9 P.S. Comment below with the latest pharma/biotech news you came across. #pharma #cdmo #biotech

In case you missed it, we’re thrilled to share that Domain Therapeutics has been featured in Labiotech.eu’s recent article highlighting the experts in GPCR-targeting immunotherapies! GPCRs are pivotal to numerous physiological and pathological processes, making them highly attractive drug targets. To date, GPCRs account for around 30% of marketed drugs addressing CNS, cardiovascular and metabolic diseases. Moreover,  many more GPCR-targeting drugs are currently under clinical and preclinical studies. In #ImmunoOncology, GPCRs play a crucial role in modulating tumor immunosuppression, thereby influencing tumor growth and metastasis. At Domain, we’re pioneering the development of innovative immunotherapies that target immunomodulation to overcome limitations of existing treatments and optimize their efficacy. Our scientifically validated platform identifies and validates GPCRs involved in immunosuppression, ensuring that the most efficient immunotherapies reach patients. With our robust biomarker strategy, we ensure optimal positioning of each therapy, targeting the most relevant indications and patient subpopulations. The GPCR market is growing rapidly! According to Grand View Research, Inc, it was valued at USD 3.46 billion in 2022 and projected to rise at a compound growth annual rate of 5.1% from 2023 to 2030. Our commitment to innovation and solid expertise in GPCRs has led to the development of novel modalities with improved GPCR selectivity, such as Allosteric Modulator or biased ligands and we’re just getting started! A big thank you to Labiotech for spotlighting Domain! Stay tuned as we continue to push the boundaries of science and medicine. Check out the full article in the comments to see how we are shaping the future of patient care! #HealthInnovation #Biotechnology #ImpactInvesting #DrugDevelopment #ValueInvesting